Associations of physical activity levels with fatigue in people with inflammatory rheumatic diseases in the LIFT trial
Rheumatology Advances in Practice · 07.06.2024 · 8 (3)
DOI: 10.1093/rap/rkae106 ↗Kurz gefasst
Fachartikel in der Zeitschrift Rheumatology Advances in Practice, online erschienen am 24.08.2024. Verfasst von Stuart R Gray und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Versus Arthritis.
Abstract (Originalsprache)
Objectives
The overall aim of the current study was to quantify physical activity levels in inflammatory rheumatic diseases (IRDs) and to explore their role in fatigue.
Methods
We conducted a secondary analysis of data from the Lessening the Impact of Fatigue in IRDs (LIFT) trial of the personalized exercise program (PEP) intervention for fatigue. Participants with IRDs were recruited from 2017 to 2019 and the current analysis used fatigue, measured by the Chalder Fatigue Scale (CFS) and the Fatigue Severity Scale (FSS), and accelerometer measured physical activity data collected at baseline and at the 6-month follow-up. Physical activity levels were quantified and associations with fatigue and effects of PEP investigated.
Results
Of the 337 included participants, 195 (68.4%) did not meet the current recommendations for moderate–vigorous physical activity (MVPA). In baseline cross-sectional analysis, many dimensions of physical activity were associated with fatigue. After mutual adjustment, overall physical activity (vector magnitude) was associated with CFS [−0.88 (95% CI −0.12, −1.64)] and distribution of time spent at different activity intensities was associated with FSS [−1.16 (95% CI −2.01, −0.31)]. Relative to usual care, PEP resulted in an increase in upright time, with trends for increases in step count and overall physical activity. People who increased overall physical activity (vector magnitude) more had greater improvements in CFS and FSS, while those who increased step count and MVPA more had greater improvements in FSS.
Conclusion
Increasing physical activity is important for fatigue management in people with IRDs and further work is needed to optimize PEPs to target the symptoms and impact of fatigue.
Trial registration
ClinicalTrials.gov (http://clinicaltrials.gov), NCT03248518.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK.
- Integrative Physiology and Health Science Department, Alma College, Alma, MI, USA.
- School of Infection and Immunity, University of Glasgow, Glasgow, UK.
- Department of Physiotherapy and Paramedicine, Glasgow Caledonian University, Glasgow, UK.
- Aberdeen Centre for Arthritis and Musculoskeletal Health, University of Aberdeen, Aberdeen, UK.
ORCID-Profile: Stuart R Gray, Stefan Siebert
Förderung
- Versus Arthritis
Zitieren
APA
Gray, S. R., Montoye, A. H. K., Vondrasek, J. D., Neph, S., Siebert, S., Paul, L., Bachmair, E. M., & Basu, N. (2024). Associations of physical activity levels with fatigue in people with inflammatory rheumatic diseases in the LIFT trial. Rheumatology Advances in Practice, 8(3). https://doi.org/10.1093/rap/rkae106
Vancouver
Gray SR, Montoye AHK, Vondrasek JD, Neph S, Siebert S, Paul L, et al. Associations of physical activity levels with fatigue in people with inflammatory rheumatic diseases in the LIFT trial. Rheumatology Advances in Practice. 2024;8(3). doi:10.1093/rap/rkae106
BibTeX
@article{Gray2024,
author = {Gray, Stuart R and Montoye, Alexander H K and Vondrasek, Joseph D and Neph, Sylvia and Siebert, Stefan and Paul, Lorna and Bachmair, Eva M and Basu, Neil},
title = {Associations of physical activity levels with fatigue in people with inflammatory rheumatic diseases in the LIFT trial},
journal = {Rheumatology Advances in Practice},
year = {2024},
volume = {8},
number = {3},
doi = {10.1093/rap/rkae106}
}
EUVIMED